GlaxoSmithKline says its sales of drugs and vaccines in China tumbled in the third quarter as it was hit by bribery investigations there.
Worldwide sales, it says, were flat as growth in the U.S. and Europe helped offset China’s 61 percent drop. Total revenue rose 1 percent to 6.51 billion pounds ($10.5 billion).
Read Full Article HERE
The Associated Press via CHINA US Focus http://feedproxy.google.com/~r/ChinaUsFocus/~3/eCxKqWkGL3w/
No comments:
Post a Comment